cannabis investment – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Wed, 11 Aug 2021 15:35:23 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.5 ScottsMiracle-Gro Announces Creation of New Investment Entity to Enable Investments in the Cannabis Industry https://mjshareholders.com/scottsmiracle-gro-announces-creation-of-new-investment-entity-to-enable-investments-in-the-cannabis-industry/ Wed, 11 Aug 2021 15:35:23 +0000 https://www.cannabisfn.com/?p=2929111

Ryan Allway

August 11th, 2021


The Hawthorne Collective to Invest $150 million in Canadian-based RIV Capital

MARYSVILLE, Ohio, Aug. 10, 2021 (GLOBE NEWSWIRE) — The Scotts Miracle-Gro Company (NYSE: SMG) announced today the creation of a newly formed subsidiary, The Hawthorne Collective, which will focus on strategic minority investments in areas of the cannabis industry not currently pursued by The Hawthorne Gardening Company. To that end, The Hawthorne Collective will provide a $150 million convertible loan to Toronto-based RIV Capital (TSX: RIV) (OTC: CNPOF), a cannabis investment and acquisition firm currently listed on the Toronto Stock Exchange.

“The addition of The Hawthorne Collective into our portfolio allows us to explore and pursue new opportunities in an industry that is poised for significant growth in the years ahead,” said Jim Hagedorn, chairman and chief executive officer. “With full appreciation of current banking and legal requirements, The Collective is designed to allow us to eventually participate directly in a larger marketplace as the legal environment changes over time.”

The strategic investment in RIV Capital is in the form of a six-year convertible note.  The note accrues interest at 2.03% percent annually for the first two years and includes additional follow-on investment rights. Upon conversion, The Collective, and thus ScottsMiracle-Gro, would own approximately 42 percent of RIV Capital.

The Collective will also have the right to nominate up to three members to RIV Capital’s Board of Directors, which will be increased to seven. Neither The Collective nor ScottsMiracle-Gro will have an active day-to-day role in RIV Capital nor the companies in which it invests.

In filings with Canadian regulators and the Toronto Stock Exchange, RIV Capital indicated it would use the funds provided by The Collective for general corporate and other lawful purposes, which could include additional investments and acquisitions. Upon close, RIV Capital will become The Collective’s preferred vehicle for future investments that are not currently in the purview of The Hawthorne Gardening Company. The transaction is expected to close in the fourth quarter of 2021.

“By making a minority, non-equity investment in RIV Capital, this initial transaction will have little near-term impact on our financial performance,” Hagedorn said. “While this approach means we will employ capital that won’t be available for near-term investments with a more immediate return, we are confident our partners at RIV Capital and our long-term approach ultimately will drive meaningful value for our shareholders.”

“Indeed, the growth of The Hawthorne Gardening Company over the past six years has generated significant shareholder value. It also has allowed us to develop a rare level of expertise and insight regarding the cannabis space without being involved in the plant-touching aspects of the industry. That is why we are beginning to invest in other areas of the industry through The Collective while continuing to pursue near-in strategic acquisitions to fold into the existing Hawthorne Gardening business.”

About ScottsMiracle-Gro
With approximately $4.1 billion in sales, the Company is one of the world’s largest marketers of branded consumer products for lawn and garden care. The Company’s brands are among the most recognized in the industry. The Company’s Scotts®, Miracle-Gro® and Ortho® brands are market-leading in their categories. The Company’s wholly-owned subsidiary, The Hawthorne Gardening Company, is a leading provider of nutrients, lighting and other materials used in the indoor and hydroponic growing segment. Another wholly-owned subsidiary, The Hawthorne Collective, has been established to invest in emerging areas of the cannabis industry. For additional information, visit us at www.scottsmiraclegro.com.

About RIV Capital
RIV Capital is an investment and acquisition company specializing in cannabis with a portfolio of 13 companies across various segments of the cannabis value chain. We believe that bringing together people, capital, and ideas raises the potential of the entire cannabis industry. By leveraging our industry insights, in-house expertise, and thesis-driven approach to investing, we aim to provide shareholders with exposure to specialized and disruptive cannabis companies.

Cautionary Note Regarding Forward-Looking Statements 
Statements contained in this press release, other than statements of historical fact, which address activities, events and developments that the Company expects or anticipates will or may occur in the future, including, but not limited to, information regarding the future economic performance and financial condition of the Company, the plans and objectives of the Company’s management, and the Company’s assumptions regarding such performance and plans are “forward-looking statements” within the meaning of the U.S. federal securities laws that are subject to risks and uncertainties. These forward-looking statements generally can be identified as statements that include phrases such as “guidance,” “outlook,” “projected,” “believe,” “target,” “predict,” “estimate,” “forecast,” “strategy,” “may,” “goal,” “expect,” “anticipate,” “intend,” “plan,” “foresee,” “likely,” “will,” “should” or other similar words or phrases. Actual results could differ materially from the forward-looking information in this release due to a variety of factors, including, but not limited to:

  • The ongoing COVID-19 pandemic could have a material adverse effect on the Company’s business, results of operation, financial condition and/or cash flows;
  • Compliance with environmental and other public health regulations or changes in such regulations or regulatory enforcement priorities could increase the Company’s costs of doing business or limit the Company’s ability to market all of its products;
  • Damage to the Company’s reputation or the reputation of its products or products it markets on behalf of third parties could have an adverse effect on its business;
  • If the Company underestimates or overestimates demand for its products and does not maintain appropriate inventory levels, its net sales and/or working capital could be negatively impacted;
  • If the Company is unable to effectively execute its e-commerce business, its reputation and operating results may be harmed;
  • Because of the concentration of the Company’s sales to a small number of retail customers, the loss of one or more of, or significant reduction in orders from, its top customers could adversely affect the Company’s financial results;
  • Climate change and unfavorable weather conditions could adversely impact financial results;
  • Certain of the Company’s products may be purchased for use in new or emerging industries or segments and/or be subject to varying, inconsistent, and rapidly changing laws, regulations, administrative practices, enforcement approaches, judicial interpretations and consumer perceptions;
  • The Company’s operations may be impaired if its information technology systems fail to perform adequately or if it is the subject of a data breach or cyber-attack;
  • The Company may not be able to adequately protect its intellectual property and other proprietary rights that are material to the Company’s business;
  • In the event the Third Restated Marketing Agreement for consumer Roundup products terminates, or Monsanto’s consumer Roundup business materially declines the Company would lose a substantial source of future earnings and overhead expense absorption;
  • Hagedorn Partnership, L.P. beneficially owns approximately 25% of the Company’s common shares and can significantly influence decisions that require the approval of shareholders;
  • Acquisitions, other strategic alliances and investments could result in operating difficulties, dilution and other harmful consequences that may adversely impact the Company’s business and results of operations.

Additional detailed information concerning a number of the important factors that could cause actual results to differ materially from the forward-looking information contained in this release is readily available in the Company’s publicly filed quarterly, annual and other reports. The Company disclaims any obligation to update developments of these risk factors or to announce publicly any revision to any of the forward-looking statements contained in this release, or to make corrections to reflect future events or developments.

Contact:
Jim King
Executive Vice President
Investor Relations & Corporate Affairs
(937) 578-5622

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
High Tide Announces Addition to the Horizons Marijuana Life Sciences Index ETF (TSX: HMMJ ) and Results of Annual General Meeting https://mjshareholders.com/high-tide-announces-addition-to-the-horizons-marijuana-life-sciences-index-etf-tsx-hmmj-and-results-of-annual-general-meeting/ Fri, 30 Jul 2021 14:21:34 +0000 https://www.cannabisfn.com/?p=2927836

Ryan Allway

July 30th, 2021


Calgary, AB, July 30, 2021 / CNW / − High Tide Inc. (“High Tide” or the “Company”) (TSXV: HITI) (Nasdaq: HITI) (FRA: 2LYA), a retail-focused cannabis corporation enhanced by the manufacturing and distribution of consumption accessories, today announced that as per the recently disclosed listing of holdings available on its website, the Company’s shares have now been included in Horizons Marijuana Life Sciences Index ETF (TSX: HMMJ).

“We are very pleased to have our shares included in the Horizons Marijuana Life Sciences Index ETF,” said Raj Grover, President and Chief Executive Officer of High Tide.  “This is yet more recognition of High Tide’s continued execution which has now resulted in another high profile institution acquiring our shares since we listed them on the Nasdaq.  This inclusion represents the second new ETF listing for High Tide since our shares began trading on the Nasdaq two months ago,” added Mr. Raj Grover.

Voting Results from Annual General and Special Meeting of Shareholders

The Company also released voting results from its Annual General and Special Meeting of Shareholders held virtually on Thursday, July 29, 2021 (the “Meeting”). All nominees included in its Notice of Annual General and Special Meeting of Shareholders and Management Information Circular dated June 14, 2021 (the “Circular”), were elected as directors of High Tide.

The results of the votes were as follows:

 Nominee Votes For:
Number
% Votes Withheld:
Number
%
Harkirat (“Raj”) Grover 6,700,845 99.92 5,474 0.08
Nitin Kaushal 6,701,438 99.93 4,906 0.07
Arthur Kwan 6,690,168 99.76 16,176 0.24
Christian Sinclair 6,702,172 99.94 4,172 0.06
Andrea Elliott 6,701,438 99.93 4,906 0.07

All other resolutions included in the Circular were successfully approved by shareholders at the Meeting, including but not limited to the appointment of Ernst & Young LLP as the Company’s auditor, fixing the number of directors at five and to consider the passing of other resolutions if deemed advisable, with or without variation.

Grant of Restricted Share Units

The Company also announced that its Board of Directors has approved a grant of 35,000 restricted share units (“RSUs”) to an officer of the Company pursuant to the Company’s restricted share unit plan. Each RSU entitles the holder to acquire one common share of the Company upon vesting.

About High Tide Inc.

High Tide is a retail-focused cannabis company enhanced by the manufacturing and distribution of consumption accessories. The Company is the most profitable Canadian retailer of recreational cannabis as measured by Adjusted EBITDA[1], with 88 current locations spanning Ontario, Alberta, Manitoba and Saskatchewan.  High Tide’s retail segment features the Canna Cabana, Meta Cannabis Co., Meta Cannabis Supply Co. and NewLeaf Cannabis banners, with additional locations under development across the country. High Tide has been serving consumers for over a decade through its established ecommerce platforms including Grasscity.com, Smokecartel.com and Dailyhighclub.com, and more recently in the hemp-derived CBD space through CBDcity.com and FABCBD.com as well as its wholesale distribution division under Valiant Distribution, including the licensed entertainment product manufacturer Famous Brandz. High Tide’s strategy as a parent company is to extend and strengthen its integrated value chain, while providing a complete customer experience and maximizing shareholder value. Key industry investors in High Tide include Tilray Inc. (TSX: TLRY) (Nasdaq: TLRY) and Aurora Cannabis Inc. (TSX: ACB) (Nasdaq: ACB).

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

For more information about High Tide Inc., please visit www.hightideinc.com and its profile page on SEDAR at www.sedar.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this news release are forward-looking information or forward-looking statements. Such information and statements, referred to herein as “forward-looking statements” are made as of the date of this news release or as of the date of the effective date of information described in this news release, as applicable. Forward-looking statements relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (generally, forward-looking statements can be identified by use of words such as “outlook”, “expects”, “intend”, “forecasts”, “anticipates”, “plans”, “projects”, “estimates”, “envisages, “assumes”, “needs”, “strategy”, “goals”, “objectives”, or variations thereof, or stating that certain actions, events or results “may”, “can”, “could”, “would”, “might”, or “will” be taken, occur or be achieved, or the negative of any of these terms or similar expressions, and other similar terminology) are not statements of historical fact and may be forward-looking statements.

Such forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to the ability of High Tide to execute on its business plan and that High Tide will receive one or multiple licenses from Alberta Gaming, Liquor & Cannabis, British Columbia’s Liquor Distribution Branch, Liquor, Gaming and Cannabis Authority of Manitoba, Alcohol and Gaming Commission of Ontario or the Saskatchewan Liquor and Gaming Authority permitting it to carry on its Canna Cabana Inc. and KushBar Inc. businesses. High Tide considers these assumptions to be reasonable in the circumstances. However, there can be no assurance that any one or more of the government, industry, market, operational or financial targets as set out herein will be achieved. Inherent in the forward-looking statements are known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements, or industry results, to differ materially from any results, performance or achievements expressed or implied by such forward-looking statements.

The forward‐looking statements contained herein are current as of the date of this news release. Except as required by law, High Tide does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances. Any and all forward-looking statements included in this news release are expressly qualified by this cautionary statement, and except as otherwise indicated, are made as of the date of this news release.

CONTACT INFORMATION

Vahan Ajamian

Capital Markets Advisor

[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Cybin Raises C$45 Million: The Largest Go Public Capital Raise in the Canadian Psychedelic Sector https://mjshareholders.com/cybin-raises-c45-million-the-largest-go-public-capital-raise-in-the-canadian-psychedelic-sector/ Thu, 22 Oct 2020 14:03:02 +0000 https://www.cannabisfn.com/?p=2859689

Ryan Allway

October 22nd, 2020

Psychedelics, Top Story


The COMPASS Pathways Inc. (NASDAQ: CMPS) initial public offering on the NASDAQ has reinvigorated the psychedelics industry over the past couple of weeks. While COMPASS Pathways Inc. is certainly one of the largest companies in the space, there are a handful of other companies, with experienced management teams, that have raised a significant amount of capital.

Let’s take a look at Cybin’s successful capital raises thus far and why investors may want to take a closer look as it gears up to go public in the near-term.

Successful Capital Raises

Cybin raised a total of C$10.3 million through a C$3.5 million seed round and a C$6.8 million Series A round that closed in April. In June, the company entered into an amalgamation agreement with Clarmin Explorations Inc. (TSX-V: CX) to conduct a reverse takeover, set to raise C$14 million to C$21 million and ultimately list on a Canadian stock exchange.

On October 19, Cybin announced that its initial raise of between C$14 million and C$21 million was oversubscribed to C$45 million, making it the largest capital raise in the psychedelic industry in Canada to date. The private placement consisted of 60 million subscription receipts at C$0.75 a piece and was led by Stifel GMP and Eight Capital.

Click here to receive an investor presentation and receive corporate updates

“The strong interest we received from distinguished healthcare investors enabled us to exceed our original capital-raising goals,” said CEO Doug Drysdale. “The potential for psychedelic therapies to treat mental illness and addiction disorders has never been more significant. With this investment, we will continue to advance our robust pipeline of psychedelic-based products through clinical development.”

The success in raising capital comes from both a strong management team and a unique business model that’s focused on both near and long-term potential. CEO Doug Drysdale brings decades of company-building experience in the pharmaceutical space where he raised $4 billion in private and public capital and completed 15 acquisitions across three continents.

Learn more about Cybin CEO Doug Drysdale here: 

https://www.cannabisfn.com/cybin-corp-a-psychedelics-pioneer-led-by-a-biotech-veteran/

Near & Long-term Potential

Cybin seeks to be one of the first companies to bring to market a psilocybin product targeting Major Depressive Disorder (MDD); Phase 2A and Phase 2B clinical trials scheduled to begin in early 2021. To that end, the company has entered into an agreement with IntelGenx Corp. (TSX-V: IGX), licensing its sublingual film technology to deliver enhanced bioavailability of the active drug(s) in development.

A  life sciences company, Cybin is advancing both psychedelic pharmaceutical therapies as well as non-psychedelic nutraceutical products for a number of psychiatric and neurological conditions. The company is committed to leading with innovation;  developing technologies and delivery systems to achieve the desired effects of psychedelics at low dosage levels. Cybin will be conducting clinical trials to assess the safety and efficacy of all these technologies.

Click here to receive an investor presentation and receive corporate updates

Looking Ahead

Cybin raised a total of approximately C$55M million in private funding and plans to go public through a reverse merger on a Canadian stock exchange. The company is one of the best-funded companies in the psychedelic industry with both near and long-term revenue opportunities, making it a compelling addition to investor portfolios.

To learn more, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
THC BioMed Reports Growing Revenue & Profitability https://mjshareholders.com/thc-biomed-reports-growing-revenue-profitability/ Thu, 23 Apr 2020 03:05:16 +0000 https://www.cannabisfn.com/?p=2770745

Ryan Allway

April 22nd, 2020

App, Exclusive, News, Top Story


Cannabis investors had already been shifting from “unproven potential” to “profitability” over the past several quarters prior to the global health crisis. With the COVID-19 outbreak, investors have fled previous investments to profitable companies that aren’t reliant on costly or dilutive funding to sustain their operations.

THC BioMed Intl Ltd. (CSE: THC) recently recorded its second consecutive quarter of profitability along with more than $1 million in revenue. This represents profits of $88,191 for the three months ended January 31, 2020. Investors looking for exposure to the cannabis industry may want to take a closer look at the stock as an alternative to companies with high cash burn rates and losses in operations.

Click Here To Receive Updates on THC BioMed

Growing Revenue & Outlook

THC BioMed generated more than $1 million in revenue during the first two quarters of fiscal year 2020 with an average selling price of $4.20 per gram to medical patients and recreational buyers, including the Ontario Cannabis Store and BCcannabisonline. During the second quarter alone, revenue rose 163% year-over-year to $1,246,625.

“Over the last year, we have completed and started using new grow rooms to increase our output,” said President & CEO John Miller. “Our focus on high-quality, indoor-grown cannabis at reasonable prices has made our cannabis a best seller.”

The company achieved several key operational milestones over the past six months:

Sales of THC Kiss began on April 10, 2020. The cannabis beverage can be purchased by THC BioMed’s medical patients via the company’s online store.
Pure Cannabis Sticks — or filtered, paper cylinder pre-rolls — went into automated production.
A new three-year lease was signed for a property adjacent to the company’s production facility, which will be used to free up space for more production.
Its Cannabis Act license was amended to include the production and sale of cannabis edibles, topicals and extracts, opening the door to new markets.

Management believes that these operational milestones pave the way for revenue growth over the coming quarters. In particular, the launch of Cannabis 3.0 products will expand the company’s addressable market, while the production efficiencies offered by Pure Cannabis Sticks boost bottom line performance.

Click Here To Receive Updates on THC BioMed

Sustainable Profitability

THC BioMed reported net income of $88,191, gross profit before fair value adjustments of $759,959, and adjusted EBITDA of $131,549 during the second quarter, representing its second consecutive quarter of profitability—a rarity among licensed producers that have historically experienced a high cash burn rate.

Second quarter net income was lower than the $688,925 reported during the first quarter on the surface, but gross profit before fair value adjustments and adjusted EBITDA were higher than first quarter levels of $295,480 and $890, respectively. These figures suggest that the actual bottom line performance has improved quarter over quarter.

“We are proud to have achieved our second consecutive profitable quarter,” added Mr. Miller. “Our financial statements for Q2 2020 reflect the improvements we have realized in all key indicators of economic progress.”

It’s worth noting that the average price of $4.20 per gram is lower than the average prices reported for other licensed producers, which makes the profitability even more significant, as margins are lower than the competition. If industry average prices trend lower, the company doesn’t have to cut its prices in order to remain competitive.

Looking Ahead

THC BioMed Intl Ltd. (CSE: THC) is one of the few profitable licensed producers in the industry, giving them an edge over other companies that are reliant on potentially dilutive future fundraising to stay alive.

Click Here To Receive Updates on THC BioMed

Click here to read the full feature: https://bit.ly/2V2r0Se

THC BioMed Contact:
CEO: John Miller
[email protected]
844-842-6337

CFN Media Contact:

President Frank Lane
[email protected]
206-369-7050

About CFN Media
CFN Enterprises Inc. (OTCQB: CNFN) is the owner and operator of CFN Media, the leading agency and digital financial media network dedicated to the legal cannabis, CBD & Psychedelic industries.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Israel Begins Cannabis Exports to Meet Unmet Medical Needs https://mjshareholders.com/israel-begins-cannabis-exports-to-meet-unmet-medical-needs/ Wed, 25 Mar 2020 22:37:37 +0000 https://www.cannabisfn.com/?p=2767660

Ryan Allway

March 25th, 2020

App, Exclusive, News, Top Story


Israel has long been an international center for cannabis research. THC, the psychoactive ingredient in cannabis, and CBD, the plant’s predominant non-psychoactive ingredient, were first isolated and defined by Israeli researcher Dr. Raphael Mechoulam in the early 1960s. Research continued there in the following decades, and the Israeli government has contributed greatly to the country’s prominence in the global cannabis industry. 

In Israel, medical cannabis is legal while recreational use remains technically illegal, though the government decriminalized recreational use to some extent in 2017. Government agencies provide funding for cannabis research. In January 2019, the government passed a law to allow exports of medical cannabis, though the first export was announced a year later in January 2020. With that recent development, the table appears set for growth in the Israeli cannabis market. 

Click below to view more on Isracann Biosciences  – Israel’s First Pure Play Cannabis Firm

BOL Pharma is the Israeli company that announced the first export from the country, with a shipment destined for centers that specialize in the treatment of children with epilepsy and autism in the United Kingdom. The company’s CEO, Dr. Tamir Gedo, stated, “This is truly welcome news and a real breakthrough for the Israeli medical cannabis market. The Israeli cannabis industry has a huge competitive edge in the global arena, compared to many countries trying to enter the cannabis sector… Further opening of the market to exports will enable Israel to become a world leader in the coming years.”

Click Here To Receive Isracann’s Investor Presentation 

The UK legalized medical cannabis in late 2018. Since then, patients have had a hard time getting prescribed treatments in a timely fashion, with most of the supply coming from foreign countries but facing restrictive regulations. As a result, in early March 2020, the UK government announced a change in import restrictions designed to increase the flow of timely medicinal products to registered patients.

This dynamic is common throughout Europe, with countries adopting medical programs without the infrastructure, both regulatory and physical, to provide supply to its own patients. Israel, with its strategic location combined with governmental commitment to the industry, is in prime position to pick up some of the slack.

Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) is an Israeli-based cannabis company poised to enter both the Israeli domestic and the European export cannabis markets. The company is advancing its fully-funded 230,000 sq ft hybrid greenhouse cultivation project while also advancing a partnership with a late stage project consisting of approximately 200,000 sq ft of greenhouses located on over 880,000 sq ft of agricultural land. In conjunction with the cultivation projects, Isracann is developing European distribution channels while ensuring that all aspects of its business, from cultivation through processing and manufacturing, comply with European Union GMP regulations necessary for international trade. 

While laying the groundwork for an extensive European export operation, the company is certainly not foregoing the burgeoning domestic opportunity in Israel. The country, as of late 2019, had about 46,000 registered patients. Isracann expects this number to roughly double by the end of 2020, by which time the company hopes to be harvesting and distributing products.

The company recently announced a joint venture agreement with two near-term farm operations in the Sharon Plain region of Israel. The IMC-compliant farms operate under preliminary cannabis nursery and cultivation licenses and are preparing to commence planting within weeks with 160,000 sq. ft. of greenhouse canopy on two million sq. ft. of private land. The move paves the way for the company to ramp up sales faster than it expected and could help drive near- and long-term shareholder value.

In a recent two-part interview with CFN Media, Isracann Biosciences CEO Darryl Jones outlined the company’s strategy, assets, and partnerships. He talked about some of the advantages inherent in the Israeli market (ideal climate for cultivation, regulatory environment, advanced research, widespread domestic use, proximity to Europe, etc.). 

Click Here To Receive Isracann’s Investor Presentation 

Click Below to View Video Interview #1: Isracann Biosciences CEO Darryl Jones on Israel as a Cannabis Investment

Click Below to View Video Interview Part #2: Isracann Biosciences CEO Darryl Jones on How Israel became the Cannabis Research Capital of the World

The very first medical cannabis shipment from Israel to the UK marks a new era in the promising Israeli cannabis industry. With the country’s government backing research and development efforts, as well as implementing rules to encourage growth of the industry both domestically and internationally, Israel has cemented its place as a leader for the global cannabis market. The year ahead promises to be pivotal for both the industry in general, and for Isracann Biosciences in particular as the company executes its vision of a comprehensive farm-to-consumer cannabis company. Keep an eye out as the plan unfolds.

Click Here To Receive Isracann’s Investor Presentation

Click Here to Stay Up to Date with CFN Media, Your Premier Destination for Cannabis, CBD &  Psychedelic Financial Media

Isracann Biosciences Contact:

Investor Relations

Toll Free: +1 855.205.0266

CFN Media Contact:

Frank Lane President

[email protected]

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Supreme Cannabis Focuses Organization and Reduces Cost Structure to Accelerate Profitable Growth https://mjshareholders.com/supreme-cannabis-focuses-organization-and-reduces-cost-structure-to-accelerate-profitable-growth/ Tue, 11 Feb 2020 22:29:20 +0000 https://www.cannabisfn.com/?p=2762900

Ryan Allway

February 11th, 2020

App, News, Top News


  • Corporate positions decreased by approximately 33% and operational positions decreased by approximately 13%
  • Total number of positions decreased by approximately 15% across the Company
  • New structure focuses the business on accelerating revenue growth in the Canadian market

TORONTO, February 11, 2020 – The Supreme Cannabis Company, Inc. (“Supreme Cannabis” or the “Company”) (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) today announced the implementation of a new operating structure, including staff reductions, to drive efficiencies and support long-term, profitable growth.

As previously announced on January 6, 2020, Supreme Cannabis’ board and management team are focused on achieving greater efficiencies and speed to market by rightsizing production, overhead and capital expenditures. At a corporate, operational and international level, the Company’s management team is focusing its businesses and implementing new operating models that prioritize near-term revenue growth in the Canadian market.

“As Interim President and CEO, I committed to take immediate steps to position Supreme Cannabis for long-term success, including rightsizing the Company’s cost structure and focusing our efforts on near-term revenue-generating opportunities,” said Colin Moore, Director and Interim President and CEO. “Recent staff reductions were an extremely difficult decision for myself and the Board, but I believe them to be necessary to create a more agile, focused and profitable organization for the long-term benefit of all of Supreme Cannabis’ stakeholders. The changes we are implementing will empower our people, drive value for our shareholders and ensure that we continue to deliver a consistent and premium product to our consumers.”

Under the new optimized organization, reporting structures at the corporate level are being streamlined and vendor contracts and support services have been rationalized. Focusing the Company on near-term revenue generating opportunities and creating a more nimble and effective corporate structure resulted in a 33% reduction in employee headcount at a corporate level. In addition to ongoing improvements to the Company’s operational efficiencies, Supreme Cannabis has begun implementing a flatter organizational structure and cost-saving measures across its operating assets, including a reduction in the number of positions at the operational level of approximately 13%. Across the Company, the total number of positions have decreased by approximately 15%.

As part of management’s enhanced focus on domestic operations and prioritizing near-term profitability, the Company exited its investment in Supreme Heights, its UK and European cannabis investment platform, by exercising its retractable rights to return all investments back to the Company. Supreme Cannabis will continue to achieve capital-light, international exposure to the global wellness and medical markets through its Truverra business and MG Health Lesotho investment.

As previously announced, the Company will provide its second quarter financial results for the three and six months ended December 31, 2019, as well as an update on its plan for accelerated revenue growth and strategy to support its transition into a premium cannabis CPG company, after markets close on February 13, 2020.

About Supreme Cannabis.

The Supreme Cannabis Company, Inc., (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), is a global diversified portfolio of distinct cannabis companies, products and brands. Since 2014, the Company has emerged as one of the world’s fastest-growing, premium plant-driven lifestyle companies. Supreme Cannabis’ portfolio of brands caters to diverse consumer experiences, with brands and products that address recreational, wellness, medicinal and new consumer preferences.

The Company’s brand portfolio includes, 7ACRES, Blissco, Truverra, Sugarleaf by 7AC and Khalifa Kush Enterprises Canada. Supreme Cannabis’ brands are backed by a focused suite of world-class operating assets that serve key functions in the value chain, including, scaled cultivation, value-add processing, centralized manufacturing and product testing and R&D. Follow the Company on Instagram, Twitter, Facebook, LinkedIn and YouTube.

We simply grow better.

Forward-Looking Information.

Certain statements made in this press release may constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information may relate to anticipated events or results including, but not limited to: the ability to drive shareholder value; continuing to deliver a consistent and premium product to consumers; winding down its investment in Supreme Heights; continuing to achieve capital-light international exposure to the global wellness and medical markets; and other statements that are not historical facts. Particularly, information regarding our expectations of future results, targets, performance achievements, prospects or opportunities is forward-looking information. Often, but not always, forward-looking information can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “believe”, “estimate”, “plan”, “could”, “should”, “would”, “outlook”, “forecast”, “anticipate”, “foresee”, “continue” or the negative of these terms or variations of them or similar terminology. Forward-looking information is current as of the date it is made and is based on reasonable estimates and assumptions made by us at the relevant time in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. However, we do not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws in Canada. There can be no assurance that such estimates and assumptions will prove to be correct. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking information, including, without limitation, the factors discussed in the “Risk Factors” section of the Company’s Annual Information Form dated September 17, 2019 (“AIF”). A copy of the AIF and the Company’s other publicly filed documents can be accessed under the Company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. The Company cautions that the list of risk factors and uncertainties described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information.

SOURCE The Supreme Cannabis Company, Inc.

More Information.

Madelin Daviau, Investor Relations
Email: [email protected]
Phone: 416-466-6265
supreme.ca

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
The Future of Cannabis Retail Is Here https://mjshareholders.com/the-future-of-cannabis-retail-is-here/ Tue, 11 Feb 2020 21:58:16 +0000 https://www.cannabisfn.com/?p=2762890

Robin Lefferts

February 11th, 2020

App, Exclusive, Top Story


Cannabis has been grown and sold illicitly for generations in California. But legal sales of cannabis through retail stores is still relatively new. With black- and gray-market sellers as precursors, most cannabis dispensaries today don’t stray far from the old-school medical dispensary or head-shop model – cramped and crammed with a wide variety of products pushed together on whatever shelf space is available, with little to no organization. In addition, there is a lack of in-store education about products, and the traditional marijuana culture can be intimidating for the novice cannabis consumer.

With a precedent that leaves so much to be desired, cannabis retail is ripe for disruption and reinvention. CalEthos (OTC: BUUZ) is a Southern California company stepping up to the challenge, with its innovative SHOWCASE cannabis retail store and event center concept.

In a traditional dispensary, cannabis brands have a difficult time developing brand identity or connecting with consumers. There are a lot of nascent brands competing for limited shelf space, advertising and promotion is often restricted, and there is no real in-store representation or consumer education. 

For consumers, typical dispensaries can be uncomfortable, high-pressure environments, with little room or time to browse, and little access to product expertise or education.

The SHOWCASE cannabis superstores and event centers planned by CalEthos were specifically conceived to respond to all of those pain points. With a focus on large-format spaces, direct brand representation, and accessible consumer education, the company is changing the way cannabis retailing is done. 

Click Here to Receive a CalEthos Investor Presentation & Company Updates

CalEthos is in the process of financing its first SHOWCASE location, with a building and the appropriate licenses already secured. Nine more stores are planned across Southern California in the next three years, an expansion that would permanently change the face of cannabis retail in the region making CalEthos one of the dominant retailers in the market. 

Click the Video Above to Step Inside the SHOWCASE Cannabis Superstore and Event Center Virtual Reality Tour

Giving Brands a Voice

Before developing the model for CalEthos’ SHOWCASE venues, company founders took the time to listen to the hurdles facing cannabis product companies as they look to build their brands. Overwhelmingly, they heard the same main issues from the leading brands in California — inadequate product display and representation and no way to connect with consumers and educate them on products. 

A diversified brand may produce a dozen or more strains of cannabis flower, along with lines of pre-rolls, concentrates, vapes, topicals, beverages or edibles. A leading California cannabis brand can have 100 or more distinct products or SKUs. 

But in a traditional dispensary, that brand may only be given the space to represent a few SKUs at a time. Those products will usually be mixed in with a multitude of other brands, and there are no real incentives for dispensary workers to highlight or educate consumers about any particular product, especially when there is a line of customers waiting for service. In short, there is limited opportunity to build brand recognition and loyalty through retail dispensaries today.

Click Here to Receive a CalEthos Investor Presentation & Company Updates

CalEthos’ SHOWCASE stores flip the current model on its head. Each store will feature 20,000 square feet of floor space. That space will be divided up into a number of functions – retail showroom, pharmacy, event center, cafe and lounges – to give consumers an optimal experience. But the biggest innovation is in how SHOWCASE stores cater to brands.

For a fee, a brand can occupy its own in-store boutique, or command a section in a kiosk or display area dedicated to a specific product type (vape, concentrates, flower/pre-roll, CBD, edibles or beverages) where they control what products are available. With the luxury of dedicated space, brands will be able to display entire product lines and introduce them directly to browsing consumers. Each boutique or product section is staffed by a brand ambassador trained in the details of each company’s products. 

Imagine the make-up department at Nordstrom, with its Clinique, M.A.C., and Estee Lauder counters. Or the Samsung and Sony “experience shops” in Best Buy. Similarly, brands in a SHOWCASE venue can feature their products exclusively and reach consumers directly via product experts, without the expense and complication of their own retail location. Additionally, brands can use the SHOWCASE event center to highlight their products and participate in daily educational classes, workshops, seminars, and fun promotional events on everything cannabis.

3-D rendering of the Santa Ana, California SHOWCASE store

The model is advantageous for CalEthos as well, giving the company the ability to develop a large retail space with some amount of revenue certainty derived from brand membership fees. 

Cannabis Consumers the Real Winners

But cannabis consumers — and especially novice or casual “canna-curious” consumers — are the real winners here. In a SHOWCASE store, the open and inviting space allows customers to relax, explore, and learn as they shop. The pharmacy offers free medical consultation to consumers interested in using cannabis as an alternative or addition to conventional remedies. An inviting cafe and comfortable lounge areas encourage extended visits. And the event center’s daily offerings lure those seeking more knowledge and community. 

Compared to the typical Southern California retail cannabis shopping experience, SHOWCASE provides an appeal and attractions to drive significantly larger foot traffic and intense customer loyalty.

CalEthos’ unique approach is summed up in its motto – “Giving brands a voice and consumers an educated choice.”

The Plan for Southern California

CalEthos is focused solely on Southern California, the largest legal cannabis market in the world. With more than 20 million residents and 142 million visitors annually, the four most populous counties in the region (Los Angeles, San Diego, Orange, and Riverside) provide CalEthos a very large consumer base to deploy its SHOWCASE business model. California is the trendsetter for the world in general, and the cannabis industry in particular. It’s the best place to launch a new cannabis retail model.

The next step is opening the company’s first store in Santa Ana to serve 3.2 million Orange County residents and 40+ million visitors per year, currently in the funding phase.

Click Here to Receive a CalEthos Investor Presentation & Company Updates

The Upshot

Businesses succeed when they find gaps and pain points in a market, then solve them. CalEthos has identified several such pain points, for both brands and consumers, and conceived one elegant retail response to them all.

While other retail industries have struggled with the rise of e-commerce and direct-to-consumer brands, brick-and-mortar experiences remain critical in cannabis. As the industry looks to expand and thrive beyond the niche pot culture, innovation in retail learning and shopping experiences will be essential. CalEthos is driving that kind of innovation, and it looks to prove its concept across Southern California. Stay tuned…

Ready to SHOWCASE your Brand? Click Here to Apply.

For Additional Information on CalEthos Please Visit the website at: https://www.calethos.com

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Avatar

About Robin Lefferts


]]>
Supreme Cannabis 2020, A Simple Approach On The Path To Profitability https://mjshareholders.com/supreme-cannabis-2020-a-simple-approach-on-the-path-to-profitability/ Thu, 23 Jan 2020 00:28:20 +0000 https://www.cannabisfn.com/?p=2761804

Ryan Allway

January 22nd, 2020

App, Exclusive, News, Top Story


Many expect 2020 to go down as the shakeout year for the Canadian cannabis industry; the year where winners will make their way to the top and companies with weak fundamentals will be ruled out. Of the potential winners, The Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) is one Canadian player that stands out with its simple yet differentiated approach,  strong core business and focused growth drivers. 

In 2019, the company built the infrastructure, developed the brands and attracted the people necessary to establish a winning Canadian cannabis business. In 2020, a few key drivers are accelerating the company forward and setting it apart from other players in the space: 

  1. Realizing scaled efficiencies with construction on flagship facility complete 
  2. Transitioning to a high-margin CPG business with consumer-facing brands 
  3. Gaining recreational market share with new brands and product formats 
  4. Delivering 2.0 products that showcase high-quality cannabis inputs 
  5. Relying on a proven team from operations to the c-suite

1. Realizing scaled efficiencies with construction on flagship facility complete 

With the completion of the company’s flagship 7ACRES facility in Kincardine, Ontario, Supreme Cannabis joins the small list of licensed producers with fully built-out operating assets and is first on the list of producers with a scaled cultivation asset capable of producing premium cannabis. 

This 440,000 square foot facility includes administrative areas, processing space and of course almost 250,000 square feet of cultivation space. In order to maintain a premium product, the company takes a small-batch approach to cultivation, growing in rooms no larger than 10,000 square feet, completing a full plant 2-week dry, and finishing the cannabis with a hand-trim.  

With construction complete, 7ACRES has the ability to maintain its premium practices while truly benefitting from scale; operating at scale brings about production efficiencies, increases the number of harvests per week and allows for greater automation and other advancements that help both top and bottom lines.

From the beginning, the company aimed to build meaningful square feet, not the most square feet. As the industry enters into an anticipated period of oversupply, Supreme Cannabis’ approach to premium cultivation is more important than ever. 7ACRES’ differentiated high-end product makes the company less susceptible to the pricing pressures the industry is facing.  

  1. Transitioning to a high-margin CPG business with consumer-facing brands 

With construction complete, Supreme Cannabis also gains additional packaging capacity at the 7ACRES facility. Since inception, packaging constraints have left 7ACRES dependent on making bulk wholesale sales to other licensed producers. With a desirable premium product, strong consumer brands and greater packaging capacity online, Supreme Cannabis is now able to transition to 100% consumer-facing sales and capture more attractive recreational margins.

With 100% consumer-facing sales expected by the company’s fiscal Q3 (January 2020 to March 2020), management is on track to transform Supreme Cannabis from a wholesale supplier to a consumer packaged goods (CPG) company. There is nothing subtle about the change and the increased capacity, as the integration allows 7ACRES to sell all products into the lucrative recreational market directly to retailers that currently are having difficulty keeping popular – and award winning – 7ACRES products in stock.

After recently inking deals to supply retailers in Quebec and Newfoundland and Labrador, 7ACRES products are now available throughout all of Canada. With additional distribution opportunities, the company intends to install two new bottling lines at the facility during the current fiscal year (which runs through to June 2020), further increasing 7ACRES’ output.

  1. Gaining recreational market share with new brands and product formats 

In July 2019, Supreme Cannabis closed the acquisition of wellness cannabis brand Blissco. The company subsequently installed a large-scale ethanol extraction system in addition to the existing CO2-based extraction system Blissco was operating in British Columbia. Blissco is forecasted to have the capacity to produce 7 million tincture bottles annually.

In the first half of the calendar year (H2 of Supreme’s fiscal year), the company will begin to realize the benefits of these additional operations and new products coming online. Blissco recently launched a new full-spectrum CBD (cannabidiol) oil branded Pūr Dew. Supreme Cannabis also introduced Sugarleaf by 7AC, offering a new product format and brand for consumers seeking more convenient and accessible cannabis experiences.  

  1. Delivering 2.0 products that showcase high-quality cannabis inputs 

Also upcoming – the company expects to benefit from a full quarter of 2.0 product sales by Q4 fiscal 2020 (May-June). The first 2.0 product to market will be from a partnership struck last summer with vaporizer company Pax Labs, a market leader with over 1.5 million devices sold worldwide. Pax was proactive in penning  agreements with select producers ahead of Cannabis 2.0. In October 2019, Canada amended its cannabis regulations, allowing new products, including vaporizers, but with requisite product approvals the market is only just getting off the ground. 

Through its agreement with PAX, 7ACRES is one of only four licensed producers chosen as initial partners to create cannabis oil pods for the PAX Era. Supreme Cannabis is in good company, other initial partners include: Aurora Cannabis Inc. (TSX: ACB) (NYSE: ACB), Aphria Inc. (TSX: APHA) (NYSE: APHA) and Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI). 

  1. Relying on a proven team from operations to the c-suite 

As Supreme Cannabis and the rest of the cannabis industry mature, attracting top talent is of the utmost importance. Supreme Cannabis’ appeal and potential is clearly illustrated by the types of leaders it is attracting at every level. Most recently, John Griese joined the company as Chief Operating Office. This executive has held senior level positions in operations and supply chain with Nestle and Pepsico. In addition to John, Joel Toguri recently joined Supreme Cannabis as SVP Commercial, Joel brings over 20 years of regulated industry knowledge from both the cannabis and alcohol and beverage space. 

To achieve its vision of operating as a CPG company, Supreme has clearly been building out a strong management team, bringing in seasoned vets with success in the CPG business. On January 6, the company announced the departure of CEO Navdeep Dhaliwal and appointed Colin Moore, Supreme Cannabis director and former President of Starbucks Coffee Canada as Interim President and CEO. Moore will guide the ship while the board conducts a search to hire a new CEO to with the background to succeed in its mission for profitable, long-term growth. In the interim, there are few people better positioned than Mr. Moore to take on the role of CEO. Colin has 40 years of experience driving growth and efficiencies in consumer businesses like Starbucks, as well as deep familiarity with the Company and management team as a Board director.

Supreme Cannabis trades as FIRE on the Toronto Stock Exchange (TSX: FIRE), SPRWF on the OTC Exchange in the United States (OTCQX: SPRWF) and 53S1 on the Frankfurt Stock Exchange (FRA: 53S1). Follow Supreme on Instagram, Twitter, Facebook and YouTube.

Click here to receive a Supreme Cannabis Investor Deck and Corporate Updates

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Cannafornia strikes deal for Florida Super License, has opportunity to become one of 22 Florida Licensees https://mjshareholders.com/cannafornia-strikes-deal-for-florida-super-license-has-opportunity-to-become-one-of-22-florida-licensees/ Mon, 20 Jan 2020 15:47:32 +0000 https://www.cannabisfn.com/?p=2761766

Ryan Allway

January 20th, 2020

News, Top News


CEO of Cannafornia, Paul King, told us earlier today, “Cannafornia has made a name for itself in the most competitive market in the world, California, where there are over 6,000 active licensees, and a long history of illicit growing and selling. Despite all the challenges, Cannafornia has emerged as one of the state’s top producers of greenhouse cannabis, with a brand who’s vibrance has attracted one of the largest followings of any cannabis brand in the world, from the streets to social media and everywhere in between.”

King continued, “Cannafornia has been able to achieve profitability in a tough market where up until January 7th, the Metric system hasn’t been enforced, allowing for black market operations to continue to thrive while white market suppliers get burdened with taxes.

Despite all the challenges, Cannafornia has stuck to a lean management model where salaries are kept low, stock options are given to all employees, and the team is solely focused on the long term growth and profitability of the company.”

Cannafornia has stayed head-down and focused the past several years to establish itself in the California market. With its track record of success, Cannafornia was able to secure a deal for a Florida super license, allowing the brand to expand to the most important state in the country. With its sunny climate and super license structure, there exists a wonderful opportunity for an operator that is able to execute quickly and efficiently.

King summarized, “The timing of the opportunity is once in a lifetime in Florida, this unique set of circumstances won’t happen again. Over time it will develop and look more like California where the competition is fierce. We’re not scared of that challenge either; we did it before and we’ll do it again. But the time is now; with the knowledge we have, cross that with being a first mover in the Florida market, it’s hard to overstate how special the opportunity is. I’ll never have another one like it in my lifetime, and I’m fine with that, because I’m going to make this one count.”

King explained his funding to date. “We never raised more money than we needed, always keeping share holder dilution in mind. We’ve done a good job of that. Now we’re going out to raise for Florida, and if we’re able to secure the funds needed, we will be going full speed ahead in Florida.”

King concluded, “I’m happy about the shake up of the market recently. It simply tells the truth and clears the noise. There were too many over hyped Canadian companies. You don’t grow plants in greenhouses in the cold. It’s inefficient. It’s that simple. Thanks to the shake up, which we’ve been eagerly anticipating, those companies can’t afford to make moves in places like Florida, and that leaves few players that have the operational expertise and the fundraising ability to execute. I feel like we’re in a very very good spot to capitalize and that’s exactly what we plan to do in 2020.”

About Cannafornia

Cannafornia is one of the largest producers of greenhouse (light assisted) cannabis in the state of California. With its own 35,000 sq ft nursery and 145,000 sq ft active cultivation, with a 300,000 sq ft expansion by Q4 2020, Cannafornia develops its own genetics, takes a breed through R+D, and cultivates only the best of the best where only 1 in 10 strains are selected for the market.

Cannafornia is vertically integrated in California, holding 5 distinct types of licenses which include every part of the cannabis process except for retail, which is by design. Aside from being one of the leaders in California, Cannafornia has applied for a lottery license in Illinois and is now raising to close on the Florida license.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Investors Opening Eyes to Opportunity in Israel Cannabis, Including Exclusive CEO Video Interview Part #2 https://mjshareholders.com/investors-opening-eyes-to-opportunity-in-israel-cannabis-including-exclusive-ceo-video-interview-part-2/ Fri, 20 Dec 2019 18:52:58 +0000 https://www.cannabisfn.com/?p=2747826

Ryan Allway

December 20th, 2019

Uncategorized


There is no country on Earth that has a history steeped in cannabis research like that of Israel. Furthermore, there is no government that is more supportive of medical marijuana research than Israel. Yet, the small country has by and large gone overlooked for what it has to offer as an investment opportunity. That is until recently.

“[Israel has] broken down the barriers,” said Darryl Jones, CEO of Isracann Biosciences (CSE: IPOT) (OTC: ISCNF), in a Q&A session with CFN Media. “It’s flown under the radar for a while, but a lot of people are starting to come around and realize that Israel is a cannabis hub.”

Isracann, the first pure-play cannabis firm in Israel to list in Canada and U.S., is 100% focused on building out its fully-funded, 230,000 square-foot facility in the southern part of Israel. Isracann is working directly with Israeli Ministries and collaborating with a team of top lawyers and consultants to move the project expeditiously forward while staying on side with all regulatory processes. The company recently expanded in cultivation capacity through a new joint venture west of Be’er Sheva, Israel.

Click Here To Receive Isracann’s Investor Presentation

Birthplace of Cannabis Research

Dr. Raphael Mechoulam has rightfully earned the nickname the “Father of Marijuana Research.” More than 50 years ago, the Israeli organic chemist was the first person ever to isolate cannabidiol (CBD, a non-intoxicating compound in cannabis) and tetrahydrocannabinol (THC, the psychoactive component of cannabis). In the 1990’s, Dr. Mechoulam discovered that cannabinoids occur endogenously throughout the human body, making up the endocannabinoid system along with specific receptors.

Cannabinoids like CBD and THC, amongst more than 100 others, are compounds found in cannabis that act on cannabinoid receptors throughout the body, including the brain, nervous system, organs and tissue, to control a host of functions, such as pain management, the immune system, appetite and mood.

At 89 years of age, Dr. Mechoulam is still active in the cannabis space as a professor of Medicinal Chemistry at the Hebrew University of Jerusalem in Israel. His extensive body of work has earned him many awards, including a Lifetime Achievement Award at CannMed in 2016.

It is because of Dr. Mechoulam and his collaborators that scientists today are in the best position ever to understand regulation of the endocannabinoid system and what it can do for next-generation, cannabis-based medicines.

No Place Like It

Israel would not have its rich cannabis history if it weren’t for a supportive government. As discussed by Jones in the interview, Israel is the only country in the world where an organization can hold and independent research license and conduct studies on marijuana.

On top of friendly regulators, Mother Nature has blessed Israel with nearly perfect conditions for growing cannabis. Israel has 300+ days of sunshine each year, high UV rays and temperature and humidity that are ideal for growing the plant.

To that end, the country is highly regarded for its talent pool in agriculture and extensive infrastructure supportive of the industry.

This results in high-quality, low cost cannabis production.

Click Here To Receive Isracann’s Investor Presentation

Earlier this year, Israeli lawmakers passed legislation to allow for cannabis exports. That puts the country in elite company along with only the Netherlands and Canada as countries were cannabis exports are legal. It is expected that the framework will be in place to commence shipments in 2020.

According to Jones, the new laws will ultimately lead to Israeli technology and cannabis breaking into the European Union, getting into the hands of people that need and can benefit from it. In addition to serving the growing domestic market in Israel, Isracann has its sights set on Germany, the largest economy in the E.U. and one that has an emerging medical marijuana market.

Not Without Challenges

Jones has watched the cannabis industry in Canada unfold over the last couple decades, which brings experience to the up-and-coming market. To that point, he sees similarities between Israel and where Canada was 4-5 years ago. One of the biggest challenges for any emerging market is educating doctors and patients as to why cannabis can provide a therapeutic benefit.

Israelis are by no means completely unfamiliar with cannabis. In fact, the country has one of the highest per capita user rates in the world.

Currently, there are about 45,000 Israeli patients, with another 10,000 on a waiting list. The cannabis patient population is growing 10-15% annually, says Jones, which makes for a very attractive market opportunity immediately.

Click Here To Receive Isracann’s Investor Presentation

To learn more about Isracann Biosciences Click Here

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>